A Phase 1/2, Multi-center, Open-label Study of IMGN632 Monotherapy Administered Intravenously in Patients with CD123-positive Acute Myeloid Leukemia and Other CD123-positive Hematologic Malignancies
MD Anderson Study Status
This is an open-label, multi-center, Phase 1/2 study to determine the MTD and assess the safety, tolerability, PK, immunogenicity, and anti-leukemia activity of IMGN632 when administered as monotherapy to patients with CD123+ disease. The study is enrolling a pivotal cohort of frontline BPDCN patients and a cohort of relapsed/refractory BPDCN patients.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Blastic Plasmacytoid Dendritic Cell Neoplasm, Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, Myeloproliferative Neoplasm
For general questions about clinical trials: